VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, December 31, 2025

Stock Comparison

Abbott Laboratories vs Gilead Sciences, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$219.2B
SectorHealthcare
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Gilead Sciences, Inc.

GILD · NASDAQ Global Select Market

Market cap (USD)$155.6B
SectorHealthcare
CountryUS
Data as of2025-12-30
Moat score
74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.

View GILD analysis

Comparison highlights

  • Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
  • Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.

Primary market context

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

Gilead Sciences, Inc.

HIV

Market

HIV treatment and prevention medicines (antiretroviral therapy and PrEP)

Geography

Global (U.S. and Europe are major markets)

Customer

Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies

Role

Drug developer and marketing authorization holder

Revenue share

68.5%

Side-by-side metrics

Abbott Laboratories
Gilead Sciences, Inc.
Ticker / Exchange
ABT - New York Stock Exchange
GILD - NASDAQ Global Select Market
Market cap (USD)
$219.2B
$155.6B
Sector
Healthcare
Healthcare
HQ country
US
US
Primary segment
Cardiovascular & Electrophysiology Devices
HIV
Market structure
Oligopoly
Oligopoly
Market share
n/a
50%-60% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
64 / 100
74 / 100
Moat domains
Demand, Legal, Supply
Demand, Legal, Supply
Last update
2025-12-30
2025-12-30

Moat coverage

Shared moat types

Brand TrustCompliance AdvantageIP Choke Point

Abbott Laboratories strengths

Procurement InertiaInstalled Base ConsumablesData Workflow LockinGovernment Contracting RelationshipsDistribution ControlScale Economies Unit CostTraining Org Change Costs

Gilead Sciences, Inc. strengths

Habit DefaultSwitching Costs GeneralService Field NetworkCapex Knowhow ScaleRegulated Standards Pipe

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

Gilead Sciences, Inc. segments

Full profile >

HIV

Oligopoly

68.5%

Oncology (Cell Therapy + Trodelvy)

Oligopoly

11.5%

Liver Disease

Oligopoly

10.6%

Veklury (Remdesivir)

Competitive

6.3%

Other Products

Competitive

3.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.